Drexel University — James M. Burns Jr. laboratory
Drexel University’s Burns laboratory develops multivalent malaria vaccines designed to protect against more than one stage of the malaria parasite, including mRNA vaccine candidates that combine pre-erythrocytic and blood-stage antigens.
What they do
Drexel University’s Burns laboratory develops multivalent malaria vaccines designed to protect against more than one stage of the malaria parasite, including mRNA vaccine candidates that combine pre-erythrocytic and blood-stage antigens.1 Its U.S. R&D is based in Philadelphia, Pennsylvania.2,1 The work spans the discovery and development stages, with mouse proof-of-concept studies completed and NIH-funded preclinical vaccine design, development, and evaluation ongoing.1
- Philadelphia, PA1Research and development
In the field and in development
Partnerships
No endemic-country partnerships are listed.
Who they work with in the United States
- Drexel University College of Medicine, Department of Microbiology and Immunology1Philadelphia, PA · Amy Ott, vaccine design, development and testing
- Drexel Department of Biochemistry & Molecular Biology1Philadelphia, PA · Patrick Loll, lipid biochemistry
- Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology6,1In the atlasBaltimore, MD · Photini Sinnis, malaria sporozoite biology
- NIAID/NIH Laboratory of Malaria and Vector Research6,1In the atlasRockville, MD · Carole Long, malaria vaccine development
Where this comes from
- 1Confirmed by the organization
- 2pmc.ncbi.nlm.nih.gov
- 3mesamalaria.org
- 4reporter.nih.gov
- 5mdpi.com
- 6ncbi.nlm.nih.gov